According to CoinMeta, Jim Cramer stated that the combined trial results of Moderna Inc (Nasdaq: MRNA) and Merck & Co, as well as Inc (New York Stock Exchange: MRK), were encouraging. On August 19th, the stock of Merck rose by 12.6%, while the stock of Moderna rose by 176%. The trial combined Moderna's product with Merck's Keytruda cancer drug, demonstrating a synergistic effect in fighting cancer. Cramer mentioned in a program on August 24th that this progress is good news for patients. Despite Moderna facing financial challenges after the pandemic, the results of this trial have brought new hope to them.